Emerging treatments
Ixazomib: a novel drug for multiple myeloma. Zanwar S et al. Expert Rev Hematol. 2018 Sep 1. doi: 10.1080/17474086.2018.1518129. [Epub ahead of print] A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. San-Miguel JF et al. Haematologica. 2018 Sep. doi: 10.3324/haematol.2017.185991. [Epub 2018 Jun 28] Phase I study…